CD8A and neoplasm: Successful activation of naive CD8+ T cells requires presentation of pathogen-derived or tumour peptides by professional antigen-presenting cells (APCs) in the context of major histocompatibility molecule class I (MHC) molecules to the T cell receptor (TCR), in addition to receipt of co-stimulatory and inflammatory signals [1,2,3].